Elilly看到2024年Q4利润丰厚,但新的体重损失药物销售预期滞后。 Eli Lilly saw strong 2024 Q4 profits, but new weight-loss drug sales lagged expectations.

Elilly报告说,2024年最后一个季度的利润丰厚,原因是销售糖尿病和肥胖症药物。 Eli Lilly reported strong profits for the final quarter of 2024, driven by sales of diabetes and obesity drugs. 该公司预测2025年利润高于估计数,将增长归因于在更多市场上推出一种新的减重药物。 The company forecasted 2025 profits above estimates, attributing the growth to the launch of a new weight-loss drug in additional markets. 然而,减重药品的销售没有达到预期。 However, sales of the weight-loss drug fell short of expectations.